| Date Checked | 2025-12-21 23:37:04 |
|---|---|
| Graham Number | (PB)nan vs (PE)0.00 |
| Over / Under Value Percentage | 0.00% vs 0.00% |
| Dividend Yield | 0.00% |
| Dividend Date | None |
| Symbol | RXRX |
| AssetType | Common Stock |
| Name | Recursion Pharmaceuticals Inc |
| Description | Recursion Pharmaceuticals, Inc. (RXRX) is a leading clinical-stage biotechnology company headquartered in Salt Lake City, Utah, that is dedicated to revolutionizing drug discovery through the application of advanced technologies across biology, chemistry, and data science. Utilizing its proprietary platform, which integrates high-throughput automation with cutting-edge deep learning algorithms, Recursion aims to decode complex biological systems and expedite the development of novel therapies for a wide range of diseases. As a key player in the biopharmaceutical sector, the company is committed to enhancing the efficiency and effectiveness of the drug discovery process, ultimately bringing innovative treatments to market faster and more effectively. |
| CIK | 1601830 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | BIOTECHNOLOGY |
| Address | 41 SOUTH RIO GRANDE STREET, SALT LAKE CITY, UT, UNITED STATES, 84101 |
| OfficialSite | https://www.recursion.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-09-30 |
| MarketCapitalization | 2314407000 |
| EBITDA | -637875968 |
| PERatio | 0 |
| PEGRatio | None |
| BookValue | 2.129 |
| DividendPerShare | None |
| EPS | -1.84 |
| RevenuePerShareTTM | 0.109 |
| ProfitMargin | 0 |
| OperatingMarginTTM | -33.28 |
| ReturnOnAssetsTTM | -0.42 |
| ReturnOnEquityTTM | -0.911 |
| RevenueTTM | 43689000 |
| GrossProfitTTM | -503448000 |
| DilutedEPSTTM | -1.84 |
| QuarterlyEarningsGrowthYOY | 0 |
| QuarterlyRevenueGrowthYOY | -0.802 |
| AnalystTargetPrice | 7 |
| AnalystRatingStrongBuy | 1 |
| AnalystRatingBuy | 1 |
| AnalystRatingHold | 6 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 0 |
| TrailingPE | - |
| ForwardPE | - |
| PriceToSalesRatioTTM | 52.97 |
| PriceToBookRatio | 2.207 |
| EVToRevenue | 39.92 |
| EVToEBITDA | -5.31 |
| Beta | 0.937 |
| 52WeekHigh | 12.36 |
| 52WeekLow | 3.79 |
| 50DayMovingAverage | 5.03 |
| 200DayMovingAverage | 5.19 |
| SharesOutstanding | 514190000 |
| SharesFloat | 503884000 |
| PercentInsiders | 3.926 |
| PercentInstitutions | 61.357 |
| ExDividendDate | None |
| etoro | 1 |
| dateChecked | 2025-12-21 23:37:04 |
| fresh | 1 |